

Economic impact of innovative drugs for multiple sclerosis.

A real-world data analysis

/ Buigues-Pastor L¹
/ Usó-Talamantes R²
/ Alós-Almiñana M³



Universidad
Católica
de Valencia
San Vicente Mártir



Hospital Clínico
Universitario de Valencia

¹ Escuela de Doctorado. Universidad Católica de Valencia San Vicente Mártir. Spain

² Universidad Católica de Valencia San Vicente Mártir. Spain.

³ Hospital Clínico Universitario de Valencia. Valencia. Spain.

Objectives

Analyzing the impact of multiple sclerosis modifying treatments approved by the European Medicines Agency (EMA) using real-world data from the Valencia University Clinical Hospital for 2013-2018.

Methods

A database of 324,497 people resident in a health district of Valencia (Spain) was used. Each patient register contained the following information: age, diagnostic, type of treatment (start; continuation; modification; suspension), start date and end date of treatment, treatment description and posology.

Cost of treatments was calculated according to the sale price of the laboratory plus VAT by using the 3% discount rate, commonly accepted for Spain.

The analysis was made from the payer perspective.

Conclusions

Results support what has been published in the literature regarding incidence and distribution by gender.

Despite having a low participation in the volume of treatments, second-line therapeutic drugs are close to first-line in terms of economic impact. An exhaustive analysis of health outcomes is required to assess the cost effectiveness in real population to conduct prescriptions towards the most efficient therapies.




Figure 1. Type of treatment percentage distribution




Figure 2. Percentage distribution of treatments

Results

During 2013-2018, 115 patients started treatment for multiple sclerosis in the Valencia University Clinical Hospital. The economic impact of these innovative drugs amounted to 437,972.14 euros.

The type of treatment is shown in Figure 1. About gender, 30.4% were male with an average age of 42 years old while 69.6% were female with an average age of 43.

The percentage distribution of treatments is shown in Figure 2. First-line therapeutic drugs (glatiramer, interferons, teriflunomide and dimethyl fumarate) represented the 77% of treatments and the 56% of costs while second-line drugs signified the 23% of treatments and the 44% of costs.

Contact:

buigueslaia@mail.ucv.es